PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist for the treatment of diabetic nephropathies and diabetic macular oedema. .

PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. .

PF-04677490 is a potent, selective PDE1 inhibitor with IC50 of 21 nM for PDE1B.

PF-04701475 is a nove positive allosteric modulator of AMPA receptor, a prototype used to explore AMPAR-mediated pharmacology in vivo..

PF-04856264 is a potent, selective Nav1.7 blocker with IC50 of 28 nM, dispalys >1,000-fold selectivity over Nav1.5.

PF-04880594 is an inhibitor of RAF with IC50 values of 0.19 nM/0.13 nM and 0.39 nM for BRAF/BRAFV599E and c-RAF, respectively.

PF-04895162 (ICA-105665, PF 4895162) is an orally available agonist of neuronal Kv7 potassium channel, opens Kv7.2/7.3 and Kv7.3/7.5 potassium channels, also known as KCNQ2/3 and KCNQ3/5 channels.

PF-04957325 is a highly potent and selective PDE8 inhibitor, with IC50 values of 0.7 nM for PDE8A and less than 0.3 nM for PDE8B.

PF-04958242 is a novel potent, selctive, and orally-active AMPA receptor (AMPAR) positive allosteric modulator (PAM) with Ki of 170 nM, EC50 of 370 nM.

PF-04965842 is a potent JAK1 inhibitor with IC50s of 29 nM, 803 nM, > 10 000 nM and 1250 nM for JAK1, JAK2, JAK3 and tyrosine kinase (TYK) 2, respectively.

PF-04979064 is a highly potent and orally bioavailable PI3K/mTOR dual inhibitor developed through structure-based drug design. It inhibited mTOR, PI3Kα, β, δ and γ isoforms and AKT phosphorylation with IC50 as 2.64 nM, 0.395 nM, 0.111 nM, 0.122 nM and 28.

PF-04991532 (PF4991532) is a potent, hepatoselective Glucokinase (GK) activator with EC50 of 90±45 nM.

PF-05105679 is a potent, selective TRPM8 channel inhibitor with IC50 of 103 nM (human TRPM8 currents inhibition).

PF-05150122 is a potent, state-dependent, subtype selective Nav1.7 inhibitor with IC50 of 21 nM, no significant activity against Nav1.5..

PF-05180999 (PF 5180999) is a potent, selective, brain-penetrating and orally bioavailable phosphodiesterase 2A (PDE2A) inhibitor with IC50 of 1 nM.

PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease..

PF-05231023, a long-acting fibroblast growth factor 21 (FGF21) analog, is a FGF21-receptor agonist, suitable for development as a potential treatment for T2DM.

PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels (Nav1.7), with an IC50 of 31 nM.

PF-05381941 (PF 05381941, PF05381941) is a potent, dual TAK1/p38a inhibitor with IC50 of 156/186 nM respectively, with good kinome selectivity against 50 representative kinases.

PF-05661014 is a potent, selective Nav1.3 inhibitor with IC50 of 0.26 uM, shows no activity for Nav1.7 (IC50>10 uM).

PF-06263276 (PF06263276, PF 6263276) is a potent, selective pan JAK inhibitor with IC50 of 2.2, 23.1, 59.9 and 29.7 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

PF-06273340 is a highly potent, kinases elective, well-tolerated pan-Trk inhibitor with IC50 values of 6, 4, 3 nM for TrkA, TrkB, Trk C, respectively.

PF-06426779 (PF06426779) is a potent, selective IRAK4 inhibitor with IC50 of 1 nM against full-length IRAK4 kinase and cell-based IC50 of 12 nM.

PF-06446846 (PF-6446846) is a potent, highly selective inhibitor of PCSK9 translation with IC50 of 0.3 uM for inhibition the secretion of PCSK9 by Huh7 cells.

PF-06446846 (PF-6446846) is a potent, highly selective inhibitor of PCSK9 translation with IC50 of 0.3 uM for inhibition the secretion of PCSK9 by Huh7 cells.

PF-06459988 (PF06459988, PF 6459988) is a potent, selective, irreversible EGFR mutants with IC50 of 13, 7, 21 and 90 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.

PF-06648671 is a potent γ-secretase modulator with IC50 of 8.9 nM against Aβ42. PF-06648671 has favorable brain availability in rodent, which translated into excellent central exposure in human and robust reduction of amyloid β (Aβ) 42 in cerebrospinal fluid (CSF).

PF06650833 is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. PF06650833 is used to treat diseases such as rheumatoid arthritis, l

PF-06651600 malonate is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2.

PF-06678419 (PF06678419) is a potent, selective inhibitor of the Na+/citrate transporter NaCT (SLC13A5) that shows inhibition of citrate uptake in the HEKNaCT cells with IC50 of 0.44 uM.

PF-06679142 is a novel potent, orally active, α1β1γ1/α2β1γ1-isoform selective AMPK activator with Kd of 14 nM, EC50 of 22 nM for α1β1γ1-AMPK, shows minimal activity at the β2-containing isoforms (α1β2γ1, α2β2γ1, α2β2γ3).

PF-06726304 is a selective EZH2 inhibitor with Ki values of 0.7 nM and 3 nM for WT EZH2 and Y641N respectively; also inhibits H3K27me3 with the IC50 value of 15 nM.

PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

PF-06747711 (PF06747711) is a potent, selective, orally bioavailable RORC2 (RORγt) inverse agonist with IC50 of 4.1 nM.

PF-06751979 is a potent, selective, brain penetrant BACE1 inhibitor with binding IC50 of 7.3, 27-fold selectivity over BACE2.

PF-06764427 (PF06764427) is a potent, selective M1 muscarinic acetylcholine receptor (mAChR) positive allosteric modulator with EC50 of 55 nM, has no measurable agonist or PAM activity at the M2-M5 receptors at 10 uM.

PF-06795071 is a potent, selective, covalent Monoacylglycerol Lipase (MAGL) inhibitor with IC50 of 3 nM, >1,000-fold selectivity over FAAH.

PF-06807656 is a potent, selective renal outer medullary potassium channel (ROMK, Kir1.1a) inhibitor with IC50 of 61 nM for hROMK in patch-clamp assays.

PF-06815189 is a potent, selective phosphodiesterase 2 (PDE2) inhibitor with IC50 of 0.4 nM, >1,000-fold selectivity over PDE5.

PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay.

PF-06827443 (PF06827443) is a potent, orally bioavailable, and CNS-penetrant M1-selective positive allosteric modulator (PAM) with EC50 of 47 nM, shows no activity against M2-M5 at 10 uM.

PF-06855800 (PF06855800) is a potent, selective, SAM competitive, BBB-penetrant, orally active inhibitor of protein arginine methyltransferase PRMT5 with Ki of 0.02 nM.

PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.

PF-06928215 (PF06928215) is a high affinity Cyclic GMP-AMP synthase (cGAS) inhibitor with Kd of 200 nM, IC50 of 4.9 uM.

PF-152 is a potent, highly selective and orally bioavailable MMP13 inhibitor with Ki of 1.5 nM, with no activity against MMP3 (Ki>10 uM).

PF-184298 is a potent, selective dual serotonin and noradrenaline monoamine reuptake inhibitor (SNRI) with IC50 of 6 nM and 21 nM, respectively.

PF-219061 (PF 219061, PF219061) is a potent, selective agonist of dopamine D3 receptor with EC50 of 8 nM.

PF-232798 (PF-00232798) is a potent CCR5 antagonist with IC50 of <0.1 nM in gp160 fusion assay, exhibits potent broad-spectrum anti-HIV-1 activity.

PF-3450074 (PF74) is a small molecule HIV capsid protein, destabilized the viral capsid in vitro.

PF-3635659 (PF-03635659) is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist with Ki of 0.2 nM, shows potential for the treatment of chronic obstructive pulmonary disease (COPD)..

PF-3644022 is a potent and selective, freely reversible, ATP-competitive inhibitor of MAPKAP2 (MK2) with Ki of 3 nM.

PF3845yne is a Alkyne analogues of PF3845.

PF-3893787 (ZPL 3893787) is a potent and selective H4 receptor antagonist with binding Ki of 2.4 nM.

PF-4363467 (PF 04363467) is a novel highly potent, brain penetrant dopamine D3/D2 receptor antagonist with Ki of 1.3/692 nM respectively, with high selectivity for D3R versus other biogenic amine receptors.

PF-4618433 shows improved PYK2 potency, reduced p38 activity, and superior overall selectivity relative to the prototype BIRB796.

PF-46396 is a specific small-molecule inhibitor of HIV-1 Gag maturation that interferes specifically with the cleavage of the CA/SP1 (p25) Gag precursor to the mature CA (p24) protein.

PF-4708671 is a novel cell-permeable inhibitor of S6K1 (p70 ribosomal S6 kinase 1), with a Ki of 20 nM and IC50 of 160 nM.

PF-4776548 (PF-04776548) novel HIV integrase inhibitor for treatment of HIV infections..

PF-4778574 (PF4778574) is a brain penetrant, positive allosteric modulator (potentiator) of AMPA receptor with Ki of 85 nM, increases S-AMPA-evoked responses in rat primary cortical neurons with EC50 of 45-919 nM.

PF-5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε)

PF-6274484 is an inhibitor of the EGF receptor (EGFR; IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively).

PF-6689840 (PF6689840) is a potent and selective Type II PTK6/Brk inhibitor with IC50 of 54 nM in biochemical assays.

PF-6808472 (XO44) is a sulfonyl fluoride chemical probe that covalently labels a broad swath of the intracellular kinome with high efficiency.

PF-719 (PF719) is a potent, selective Pyk2 inhibitor with IC50 of 17 nM, displays 25-fold selectvity over FAK (IC50=469 nM); does not have significant inhibitory effects on recombinant MLCK2, p38, Akt1, or ROCK1, and very little inhibtion at Src family kinases (IC50>5 uM); selectively inhibits tyrosine phosphorylation of Pyk2 at 1 uM, but blocks both Pyk2 and FAK phosphorylation at 2.5 uM in A20 cells; reduces chemoattractant-induced migration of B-2 and MZ B cells.

PF-794 (PF794) is a potent, specific and ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with IC50 of 39 nM in cell-free assays.

PF-9184 is a potent, selective mPGES-1 (microsomal prostaglandin E synthase-1) inhibitor with IC50 of 16.5 nM.

PFE-360 is a novel potent, selective, brain-penetrating LRRK2 inhibitor with IC50 of 3 nM.

PFI-1 is a selective BET (bromodomain-containing protein) inhibitor for BRD4 with IC50 of 0.22 μM.

PfKRS1 inhibitor 5 is a potent, selective, oral inhibitor of P. falciparum lysyl-tRNA synthetase (PfKRS1) with IC50 of 15 nM, displays >100-fold selectivity over Human KRS (HsKRS, IC50=1.8 uM).

PFM01 (SML1735) is a small molecule that specifically inhibits endonuclease, but not exonuclease activity of MRE11, inhibits dsDNA end resection in A549 cells with IC50 of 50-75 uM, blocks the ssDNA-binding path toward the catalytic metal ions and disrupt

PFM39 (SML1839) is a small molecule that specifically inhibits exonuclease activity of MRE11, binds in the active site similar to mirin, inhibits dsDNA end resection in A549 cells with IC50 of 50-75 uM, inhibits HR without significantly increasing NHEJ..

PGC-1α activator C80 is a potent PGC-1α acetylation activator with AC50 of 3.1 uM, induces Pck1 and G6pc expression with AC50 of 11.9 uM and 12.8 uM, reduces glucose production in hepatocytes..

PGN-9856 (PGN9856) is a novel potent, selective prostaglandin EP2 receptor agonist with pKi of > 8.3, shows higi selectivity over EP1 , EP3 , EP4 , DP, FP, IP and TP receptors; displays a potency (pEC50 >8.5) and a maximal response (increase in cAMP) comp

P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.

PG-S3-001 is a small molecule STAT3 inhibitor that binds to STAT3 protein potently with Kd of 324 nM by surface plasmon resonance.

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM, >50-fold selectivity for c-Met than RTKs or STKs.

PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.

PHA-767491 (CAY10572) Hcl is a potent, ATP-competitive dual Cdc7/Cdk9 inhibitor with IC50 values of 10/34 nM.

Phen-DC 3|Phen-DC-3,Phen-DC3|DC Chemicals

Phenprocoumon is closely related to warfarin and is an anticoagulant drug used to thin the blood, or stop it from clotting.

Phenylbiguanide is a 5-HT3 receptor selective agonist with an EC50 of 3.0±0.1 μM.

Phenylpiracetam(Phenotropyl; Phenotropil) is a phenylated derivative of the nootropic drug piracetam.

PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM, and a relative binding affinity (Kd) of 150 μM in Ln229 cells.

Philanthotoxin 74 dihydrochloride (PhTx 74) is an AMPAR antagonist; inhibits GluR3 and GluR1 with IC50s of 263 and 296 nM, respectively.

Phosalone is a member of the organophosphate family of insecticides. It is used as both an insecticide and acaricide.

Phosphate and amino acid prodrug of Atazanavir gives four-fold improved AUC and eight-fold higher Ctrough values of Atazanavir.

Phosphonoacetohydroxamate (PhAH) is a potent Enolase inhibitor with IC50 of 53.2 nM and 62.3 nM for recombinant hENO1 and hENO2 respectively.

Phox-I1 is a small molecule inhibitor that targets the interactive site of p67(phox) with Rac GTPase with Kd of 100 nM.

PHY34 is a potent autophagy inhibitor with cytotoxic effects by inhibiting autophagy at a late stage (MDA-MB-435 IC50=23 nM, MDA-MB-231 IC50=5.2 nM).

PI103 is a potent inhibitor with low IC50 values against recombinant PI3K isoforms p110alpha (IC50= 2 nM), p110beta (IC50= 3 nM), p110delta (IC50= 3 nM), and p110gamma (IC50= 15 nM), less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.

PI-16552 is a potent, specific poly(ADP-ribose) glycohydrolase (PARG) inhibitor with IC50 of 1.7 uM.

PI-273 (PI273) is a potent, specific, substrate-competitive small molecule inhibitor of PI4KIIα with IC50 of 0.47 uM.

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual PI3K/mTOR inhibitor with IC50s of 20/376/204/46 nM and 186 nM for PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ and mTOR, respectively. Antitumor activity.

PI3K/mTOR Inhibitor-2 is a potent dual pan-PI3K/mTOR inhibitor with IC50s of 3.4/34/16/1 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ and 4.7 nM for mTOR. Antitumor activity.

PI3K-IN-16 is a potent and selective, orally bioavailable PI3Kβ and PI3Kδ inhibitor with cell IC50 of 12 nM (in PTEN null MDA-MB-468 cell) and 47 nM (in Jeko-1 B-cell), respectively.

PI3K-IN-8q is a potent, selective dual p110α/p110δ inhibitor with Ki app of 3.3/8.36 nM respectively.

PI3Kα-IN-1 is a potent, selective, ATP-competitive dual PI3Kα/mTOR inhibitor with IC50 of 0.5/104 nM respectively.

PI3Kα-IN-5 is a potent, selective PI3Kα inhibitor with enzyme IC50 and cell IC50 of 6 nM and 87 nM respectively, exhibits 100-fold selectivity over PI3Kβ.

PI3Kγ is required for for T-cell and B-cell as well as mast cell migration and degranulation. As such, these kinases are attractive targets for potential anti-infmamatory drugs. TASP0415914 has shown excellent results in cell based assays. It is orally av

PI3kδ inhibitor 1 is a potent and selective inhibitor of isoform of PI3Kδ; useful for treating disorders mediated by lipid kinases such as inflammation, immunol disorders, and cancer.

PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM.

PI3Kδ-IN-7n is a highly potent and selective PI3Kδ inhibitor with IC50 of 0.9 nM, displays high selectivity (>1,500-fold) over PI3Kα, PI3Kβ, PI3Kγ (IC50>1.5 uM).

PI4KIIIβ-IN-9 is a potent and selective inhibitor of PI4KIIIβ (IC50=7 nM).

PIAA is a TBK1/IKKε inhibitor with IC50 of 0.40/1.07 uM, selectively accelerates proliferation of β-cells.

Piclamilast (RP-73401) is a potent and highly selective PDE4 inhibitor with IC50 of 1.2 nM.

Pico145 is a highly potent, subtype-selective TRPC1/4/5 channels inhibitor with potency ranged from 9 to 1300 pM, depending on the TRPC1/4/5 subtype and activation mechanism.

Picoxystrobin is an methoxyacrylate strobilurin fungicide designed for the control of wide range of cereal diseases.

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes.

Pifithrin-β HBr (Cyclic Pifithrin-α HBr) is a potent p53 inhibitor with IC50 of 23 uM in an antiproliferative assay in the human ovarian carcinoma cell line, IGROV-1.

Pifithrin-μ is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.

PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.

Pim inhibitor 28 is a potent, selective inhibitor of Pim1/2 with IC50 of 0.05 nM for both, demonstrates on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD phosphorylation in KMS-12-BM multiple myeloma tumors..

PIM/AKK1-IN-1 is a potent multi-kinase inhibitor with Kd values of 35 nM/53 nM/75 nM/380 nM for Pim1/AKK1/MST2/LKB1 respectively; also inhibits MPSK1 and TNIK.

Pim-IN-22m is a potent, selective Pim1/Pim2 inhibitor with IC50 of 24/95 pM respectively.

Pimozide is an antipsychotic agent that acts as an antagonist of the D2, D3, and D4 receptors and the 5-HT7 receptor, also is an inhbitor of STAT5.

Pin1 inhibitor API-1 (API-1) is a potent, specific inhibitor of peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) and inhibits Pin1 cis-trans isomerizing activity with IC50 of 72.3 nM, displays remarkable selectivity over other peptidyl-prolyl

PIN1 inhibitor VS10 is a novel potent small molecule inhibitor of PIN1 (peptidyl-prolyl cis-trans isomerase, NIMA-interacting 1), inhibits human PIN1 isomerization with IC50 of 13.4 uM, displays >2-fold more potency than ATRA.

Pinacidil monohydrate, an antihypertensive drug, is a potassium channel activator.

Pioglitazone Hydrochloride is the hydrochloride salt preparation of Pioglitazone, a specific ligand of PPAR-γ (peroxisome proliferator-activated receptor-γ). Pioglitazone is a thiazolidinedione compound described to produce antiinflammatory and antiarteri

Piperazine Erastin is an analog of Erastin, which can induces ferroptosis in cancer cells, an iron-dependent form of nonapoptotic cell death..

Pipofezine(Azafen or Azaphen) is a potent inhibitor of the reuptake of serotonin.

Piragliatin (RO 4389620.

Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.

Pirlindole is a novel potent inhibitor of Enteroviruse that targets Viral Protein 2C, inhibits EV-B and EV-D through the inhibition of genome replication (CV-B3 EC50=9.91 uM). .

PIT-1 is a specific PIP3 antagonist that disrupts PIP3/Akt PH domain binding with IC50 of 30 uM, Kd of 43.2 uM.

Pivmecillinam(Amdinocillin pivoxil) is an orally active prodrug of mecillinam, an extended-spectrum penicillin antibiotic.

Pizuglanstat is a potent, selective prostaglandin D synthase inhibitor..

PJ-68 is a potent, selective inhibitor of arginine methyltransferase PRMT5 with IC50 of 517 nM, shows no inhibitory activity against type I PRMT family members ( (PRMT1, 3, 4, 6, and 8).

PK4C9 (Homocarbonyltopsentin) is a small-molecule stem-loop RNA structure TSL2-binding compound (EC50=16.1 uM) that increases SMN2 exon 7 (E7) splicing and rescues downstream molecular alterations in SMA cells.

PK-7088 is a small molecule mutant p53 Y220C reactivator, promotes correct folding of Y220 mutant p53 and induces expression of p53 targets p21 and the Noxa, triggers nuclear export of the pro-apoptotic Bax protein to mitochondria..

PKC-412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDFRβ, VEGFR2, Syk, PKCη, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.

PKC-IN-1 is a poent PKC beta II inhibitor with Ki of 14.9 nM, extracted from patent WO 2008096260 A1 as compound example H6..

PKC-IN-7 is a potent, selective, reversible, ATP-competitive PKCα/β inhibitor with IC50 of 4.7/3.3 nM.

PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R.

PL265 (PL-265) is a dual enkephalinase inhibitor, alleviate corneal pain and inflammation in vivo..

Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].

Plecanatide acetate is a guanylate cyclase-C (GC-C) receptor agonist, binds and activates GC-C receptor, with an EC50 of 190 nM in T84 cells. Plecanatide acetate shows an-inflammatory activity in models of murine colitis.

PLK1-IN-14f is a potent PLK1 inhibitor, exhibits potent activity against a panel cancer cell lines with GI50 values ranging from 0.30 to 0.60 uM.

Plocabulin (PM060184) is a novel tubulin-binding agent binding to αβ-tubulin dimer with nanomolar affinity, inhibits a panel of 23 tumor cell lines with GI50 of 20 pM-5 nM.

PM-43I is a selective inhibitor of STAT5/6 Src Homology 2 (SH2) domain, binds recombinant STAT6 and STAT5B (IC50=1.8 and 3.8 uM) with much lower affinity for STAT3 (IC50=29.9 uM).

PMX53 (Ac-Phe-cyclo(Orn-Pro-D-Cha-Trp-Arg)) is a potent C5a receptor (CD88) antagonist with IC50 of 20 nM, also is an agonist for Mas-related gene 2 (MrgX2) in human mast cells; PMX-53 (10 nM) inhibited C5a-induced Ca(2+) mobilization in HMC-1 cells, but at higher concentrations (>30 nM) it caused degranulation in LAD2 mast cells, CD34(+) cell-derived mast cells, and RBL-2H3 cells stably expressing MrgX2; inhibits zymosan-, carrageenan-, LPS- and antigen-induced hypernociception in rats.

PNPLA4-IN-1 is a potent, selective, and irreversible PNPLA4 inhibitor with IC50 of 1.8 uM (separated membrane proteome fraction), shows in-cell inhibition of PNPLA4 with IC50 of 11.7 uM..

PNR-7-02 is a specific inhibitor of human DNA Polymerase η (hPol η) with IC50 of 8 uM, exhibits 5-10-fold specificity for hPol η over other replicative Pols.

PNRI-299 is an inhibitor of activator protein-1 (AP-1) transcription (IC(50) of 20 microM) without affecting NF-kappaB transcription (up to 200 microM) or thioredoxin (up to 200 microM).

PNU-112455A is an ATP-competitive CDK2/5 inhibitor with Ki of 2 uM and 2 uM for cdk2·GST-cyclin E and cdk5·GST-p25 respectively, shows no activity against c-c-Met, IGR-1R, and ERK2..

PNU-159682 is a major bioactive metabolite of Nemorubicin in human liver microsomes; > 3,000-fold cytotoxic than its parent compound(MMDX and doxorubicin).

PNU-74654 is an inhibitor of Wnt/β-catenin pathway with an IC50 of 129.8 μM in NCI-H295 cell.

Polmacoxib is an inhibitor of cyclooxygenase 2 (COX-2) and the carbonic anhydrase subtypes I (CAI) and CAII.

Poloppin II is an orally active, Poloppin derivative inhibitor of protein-protein interaction via the PBD of the mitotic Polo-like kinase (PLK) with IC50 of 41 uM in FP assays, exhibits IC50 of 61 nM cellular assay for mitotic arrest.

Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain.

Polymyxin B is an antibiotic primarily used for resistant gram-negative infections.

Pomaglumetad Methionil (LY2140023 monohydrate) is the methionine amide prodrug of the mGluR2/3 agonist LY-404039 with the potential oral treatment of schizophrenia..

Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology.

Poseltinib (HM-71224, LY-3337641) is a potent and selective, covalent inhibitor of Btk with IC50 of 1.95 nM.

Potassium thioacetate is widely used as a sulfur source in the synthesis of sulfur-containing organic compounds. It has been employed for the synthesis of heterocycles, polymers, transition-metal ligands, nanoparticles, bioactive compounds and macromolecu

Potent and selective 5-HT6 receptor antagonist (pKi = 8.6).

Potent and selective inhibitor of the TGF-β type I receptor/ALK5 (IC50 = 2.5 nM). Exhibits ~ 5000-fold selectivity over p38 MAPK. Suppresses development of renal fibrosis in a unilateral ureteral obstruction model. Also reduces proteinuria, glomeruloscler

Potent and selective non-peptide vasopressin V1A receptor antagonist; devoid of agonist activity. Displays high affinity and efficacy at both rat (KI=1.6 nM) and human (KI -1.1 - 6.3 nM) V1A receptors.

Potent Pim-1 kinase inhibitor (Ki = 91 nM).

Potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM For c-Raf1, B-RafV600E and wild-type B-Raf, respectively). Displays selectivity For Raf kinases over a panel of 150 other kinases.

PP1 inhibitor C31 is a 1E7-03 analog and protein phosphatase 1 (PP1) targeting small molecule with Kd of 1.88 uM, inhibits Ebola virus (EBOV) transcription and replication.

PP-121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.

PPARα activator compound 3 is a specific PPAR activator that selectively up-regulates PPARα transcriptional activity, leading to PPARα target gene expression both in vitro and in vivo.

PPBI is a novel potent, selective, full M1 muscarinic agonist with EC50 of 5, 8, and 21 nM for human, rat, and mouse M1 receptors, respectively.

PPI-2458 is potent, specific, irreversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 0.2 nM, inhibits growth inhibition of HFLS-RA and HUVEC with IC50 of 0.04 nM.

PPTN is a potent, highly specific amtagonist of P2Y14 receptor with Ki of 0.4 nM in functional assays.

PPTN is a potent, highly specific amtagonist of P2Y14 receptor with Ki of 0.4 nM in functional assays.

PptT inhibitor 8918 (Compound 8918) is a mycobactericidal amidino-urea compound that targets phosphopantetheinyl transferase (PptT, IC50=2.5 uM), shows an MIC90 of 3.1 uM against Mtb H37Rv.

PQC 083 is a novel nerve growth factor (NGF) antagonist with IC50 of 7.0 uM, functionally inhibits NGF's effects on PC12 cell differentiation.

PR5-LL-CM01 is a novel selective, small-molecule inhibitor of PRMT5 methyltransferase with IC50 of 7.5 uM.

Pradefovir mesylate is a good substrate for liver CYP3A4. Pradefovir is converted to 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human liver microsomes with a Km of 60 μM.

Praliciguat (IW-1973, IW1973) is a potent, orally available sGC stimulator that concentration-dependently increases the production of cGMP with EC50 of 267 nM.

Pralidoxime is an antidote to organophosphate pesticides and chemicals.

Pramipexole is a partial/full D2S, D2L, D3, D4, receptor agonist with a Ki of 3.9, 2.2, 0.5, 5.1 nM.

Prednisolone is a glucocorticoid with the general properties of the corticosteroids. .

Presatovir (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor with mean EC50 of 0.43 nM against a panel of 75 RSV A and B clinical isolates.

Pridopidine (ACR16, FR-310826, ASP-2314, Huntexil) is a specific dopamine stabilizer without no partial agonism.

Prinaberel(ERB-041) is a potent and selective ERbeta agonist; being >200-fold selective for ERbeta.

Pristinamycin is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections.

PRN 473 is a novel potent, selective reversible inhibitor of Btk.

PRN1371 is an irreversible covalent FGFR1-4 kinase inhibitor, with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, 2, 3, 4 and CSF1R, respectively.

PRN371 is a novel potent, selective JAK3 inhibitor with IC50 of 0.5 nM, displays >250-fold selectivity over JAK1, JAK2, and TYK2.

PRN694 (PRN-694) is a highly selective, potent, covalent inhibitor of ITK and RLK with IC50 of 0.3 and 1.4 nM, respectively.

PrNMI is a peripherally restricted cannabinoid 1 receptor (CB1R) agonist, significantly alleviates spontaneous pain behaviors in the animals.

Proanthocyanidins are a class of polyphenols with antibacterial, antifungal and antiviral activities, which can be used in the treatment of chronic venous insufficiency, capillary fragility, sunburn and retinopathy.

Procaine is a benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodium channels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses.

Procaspase-3 activator 1541 is a small-molecule inducer of cell death that noncovalently self-assembles into chemical fibrils and activates procaspase-3 and 6 in vitro (EC50=2.4 and 2.8 uM).

Procaspase-3 activator 1541B is a specific, small molecule activator of procaspases-3 with EC50 of 1.3 uM.

Prochlorperazine is a dopamine (D2) receptor antagonist that belongs to the phenothiazine class of antipsychotic agents. It is also a highly potent typical antipsychotic.

Prodigiosin is a natural red pigment produced by numerous bacterial species, has exhibited promising anticancer activity.

Proflavine is a disinfectant bacteriostatic against many gram-positive bacteria. It is a topical antiseptic used mainly in wound dressings.

proMMP9-IN-3c is a potent and specific inhibitor of the hemopexin-like domain of MMP-9 (proMMP-9) with Kd of 320 nM.

Propanil is a widely used contact herbicide, mainly use in rice production.

Propionylcarnitine is a propionyl ester of L-carnitine.

Prostaglandin E2 is a hormone-like substance that participate in a wide range of body functions such as the contraction and relaxation of smooth muscle, the dilation and constriction of blood vessels, control of blood pressure, and modulation of inflammation.

PROTAC BET degrader-2 is a highly potent degrader of Bromodomain and Extra-Terminal (BET) proteins with an IC50 value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.

PROTAC Linker 2 is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.

Protac Linker 5 is a PROTAC linker utilized to connect the respective tyrosine kinase inhibitor (TKI) to the E3 recruiting ligand.

proTAME is a cell permeable prodrug of TAME, which is an anaphase-promoting complex/cyclosome (APC/C) inhibitor that binds to the APC preferentially suppresses APC/C(Cdc20).

Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.